SignalFDA/Bio

Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring

Elevar seeks EMA approval for lirafugratinib in FGFR2-fusion cholangiocarcinoma.

What changed

Elevar seeks EMA approval for lirafugratinib in FGFR2-fusion cholangiocarcinoma.

Why it matters

Elevar seeks EMA approval for lirafugratinib in FGFR2-fusion cholangiocarcinoma. — impact context not separately stored; see What changed.

Sources